Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 1-Year Low – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) reached a new 52-week low during trading on Monday . The company traded as low as $74.26 and last traded at $74.26, with a volume of 313 shares traded. The stock had previously closed at $77.00.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ZLDPF shares. William Blair upgraded Zealand Pharma A/S to a “hold” rating in a report on Thursday, February 27th. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st.

Zealand Pharma A/S Price Performance

The stock has a market cap of $5.27 billion, a price-to-earnings ratio of -31.46 and a beta of 0.92. The company has a 50 day simple moving average of $98.87 and a 200-day simple moving average of $110.34. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.19. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. Research analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.